 |
Introduction
Boehringer Ingelheim IT is driving innovation across our complex business landscape. We have a far reaching focus on advanced technologies and finding new ways to introduce technology to our core business processes. By embracing Big Data and AI analytics we are building new models and predictive tools that can have far reaching impact on our production processes and improve the quality, connectivity and availability of our patient solutions.
These projects are led by new teams stood up in key locations around the world. Often a mix of internal and external talent, the culture on these teams is fast paced. We use a tight collaboration across all IT disciplines, working energetically through complex paths to delivery, frequently solving problems, learning and experimenting to find new solutions and deliver the desired outcome.
Smart Process Design, Vienna Austria
Our smart process design team is leveraging the power of data to strengthen yields in previously unpredictable biopharma manufacturing. Working across multiple production facilities the team is mining data to build manufacturing simulations that can identify reasons for variability in the production process and ultimately raise yields and drive down costs.
New Therapeutic Concepts, Biberach Germany
The team working on new therapeutic concepts is introducing data and analytic tools in to the early stage drug discovery process. By working with some of the raw, early findings and by connecting those findings across projects our technology is able to make new linkages and identify patterns that can help multiple product teams uncover ideas and solutions to speed the development process.
Farmers, Ingelheim Germany
Agriculture is faced by two conflicting pressures – rising demand and increasingly scarce natural and labor resources. We are working in remote locations with devices, data collection and systematic analytics to identify and isolate early signs of health problems that risk spreading through the herd. The underlying data generated will simultaneously help identify inefficiencies that impact yields and farm productivity.
Mobinostics, Ingelheim Germany
We are working with vets to develop mobile diagnostic and treatment solutions that can allow greater reach and greater speed to treatment for remote farms all over the world. We envision the ability to run remote tests for many common diseases, analyze results within a matter of minutes and deliver detailed reports to mobile devices. The underlying records are retained electronically and can be analyzed for underlying patterns of cause to deliver preventative solutions in the future.
Pathological Speech Processing, Barcelona Spain
With the “Pathological Speech Processing” (PSP) Boehringer Ingelheim aims to develop digital tools that facilitate the process of speech and language processing by using machine learning and disease-customized algorithms. Our PSP- team based in Barcelona is developing the ability to analyze speech and language patterns that can be used to predict the development of mental diseases, such as the risk of dementias.
Biomarker-Based Patient Population, Vienna Austria
A project team in Vienna is empowering experts within the company to identify biomarkers to better characterize patient populations for clinical studies. Being able to process and analyze large amounts of data creates the potential to select the right drug for a patient. Ultimately, this is a significant step to begin the journey of personalized medicine delivering optimal individual care and better management of side effects.
PetPro, Buenos Aires, Argentina
One of our first digital products that directly addresses end users’ needs, PetPro Connect has been developed in close collaboration with our Animal Health business to connect pet owners and veterinarians, take care of follow-up appointments by video chat, quickly and easily order medication refills, and benefit from bonus programs.
Brass, Ingelheim Germany
BRASS (Benefit Risk Assessment System) uses artificial intelligence to conduct an initial analysis of adverse reactions to medications that have already been approved to identify potential side effects and undesirable events and offers a valuable decision-making tool for those working in pharmacovigilance, helping them process each case more quickly.